Patents by Inventor Françoise Baleux

Françoise Baleux has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11884708
    Abstract: The invention concerns stapled peptide inhibitors of NEMO which inhibit the Nuclear Factor ?B (NF-?B) signaling pathway and are useful as medicine candidates, in particular as anti-inflammatory or anticancer drugs.
    Type: Grant
    Filed: September 28, 2021
    Date of Patent: January 30, 2024
    Assignee: INSTITUT PASTEUR
    Inventors: Fabrice Agou, Alix Boucharlat, Yves-Marie Coic, Françoise Baleux
  • Patent number: 11472844
    Abstract: The invention relates to a peptidomimetic comprising or consisting of a D amino-acid sequence having at least 75% identity with SEQ ID NO: 1 or SEQ ID NO: 2, or variants or fragments thereof, in particular a peptidomimetic having the capability to interact at least with: neutrophils and/or neutrophil granules, and/or lactoferrin, and/or globet-cells and/or Muc2 proteins, and/or mucus and/or airway sputum. The peptidomimetic may have the capacity to adopt a multimeric, especially a trimeric, organization, and can be labelled, or associated with a reporter or a carrier entity, or associated with an active molecule. The invention also relates to a Solid-Phase Synthesis method for synthesizing a peptidomimetic of the invention, compositions comprising the same and use of the peptidomimetics as a medicamentor an inflammation marker or a neutrophilic inflammation marker.
    Type: Grant
    Filed: December 11, 2018
    Date of Patent: October 18, 2022
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), INSTITUT PASTEUR
    Inventors: Benoit Sebastien Marteyn, Yves-Marie Coic, Francoise Baleux
  • Publication number: 20220249644
    Abstract: The present invention relates to mutants of an E. coli heat-stable toxin (ST) having the following wild-type sequence: NSSNYCCELCCNPACTGCY wherein the mutant has two mutations wherein the first mutation is selected from L9K, L9N and L9T and the second mutation is A14T.
    Type: Application
    Filed: August 22, 2019
    Publication date: August 11, 2022
    Inventors: Pål Puntervoll, Françoise Baleux, Yves-Marie Coïc, Yuleima Diaz, Morten Andreas Govasli Larsen, Laurence Mulard, Arne Taxt, Ephrem Debebe Zegeye, Sandhya Srikant Visweswariah, Vishwas Mishra, Anaxee Barman
  • Publication number: 20220025002
    Abstract: The invention concerns stapled peptide inhibitors of NEMO which inhibit the Nuclear Factor ?B (NF-?B) signaling pathway and are useful as medicine candidates, in particular as anti-inflammatory or anticancer drugs.
    Type: Application
    Filed: September 28, 2021
    Publication date: January 27, 2022
    Applicant: INSTITUT PASTEUR
    Inventors: Fabrice AGOU, Alix BOUCHARLAT, Yves-Marie COIC, Françoise BALEUX
  • Patent number: 11149070
    Abstract: The invention concerns stapled peptide inhibitors of NEMO which inhibit the Nuclear Factor ?B (NF-?B) signaling pathway and are useful as medicine candidates, in particular as anti-inflammatory or anticancer drugs.
    Type: Grant
    Filed: December 22, 2016
    Date of Patent: October 19, 2021
    Assignee: INSTITUT PASTEUR
    Inventors: Fabrice Agou, Alix Boucharlat, Yves-Marie Coic, Françoise Baleux
  • Publication number: 20200369729
    Abstract: The invention relates to a peptidomimetic comprising or consisting of a D amino-acid sequence having at least 75% identity with SEQ ID NO: 1 or SEQ ID NO: 2, or variants or fragments thereof, in particular a peptidomimetic having the capability to interact at least with: neutrophils and/or neutrophil granules, and/or lactoferrin,and/or globet-cells and/or Muc2 proteins, and/or mucus and/or airway sputum. The peptidomimetic may have the capacity to adopt a multimeric, especially a trimeric, organization, and can be labelled,or associated with a reporter or a carrier entity, or associated with an active molecule. The invention also relates to a Solid-Phase Synthesis method for synthesizing a peptidomimetic of the invention, compositions comprising the same and use of the peptidomimetics as a medicamentor an inflammation marker or a neutrophilic inflammation marker.
    Type: Application
    Filed: December 11, 2018
    Publication date: November 26, 2020
    Inventors: BENOIT SEBASTIEN MARTEYN, YVES-MARIE COIC, FRANCOISE BALEUX
  • Publication number: 20190382456
    Abstract: The invention concerns stapled peptide inhibitors of NEMO which inhibit the Nuclear Factor ?B (NF-?B) signaling pathway and are useful as medicine candidates, in particular as anti-inflammatory or anticancer drugs.
    Type: Application
    Filed: December 22, 2016
    Publication date: December 19, 2019
    Inventors: Fabrice AGOU, Alix BOUCHARLAT, Yves-Marie COIC, Françoise BALEUX
  • Patent number: 10138280
    Abstract: The invention relates to polypeptides, defined through a consensus sequence, having a length from 10 to 80 amino-acid residues, and whose polypeptidic sequence comprises or consists of the consensus sequence P1(Xa)P3(Xb)P5(Xc)P6(Xd)P7 (SEQ ID NO: 1), presenting specific patterns. The polypeptides of the invention target glycosylated Muc2 proteins. The invention also relates to methods of synthesis of such polypeptides, to their nucleic acids and uses thereof. The polypeptidic sequence of the polypeptides of the invention can be part of the N-terminal sequence of a mucus-binding (MUB) domain, especially a mucus-binding (MUB) domain of several species. The invention also relates to chimeric molecule(s) comprising such polypeptides, which are labelled, and vectors, especially plasmids and population of cells or composition comprising polypeptides of the invention. Synthesis methods encompass biotechnological or chemical production.
    Type: Grant
    Filed: June 9, 2016
    Date of Patent: November 27, 2018
    Assignee: Institut Pasteur
    Inventors: Benoit Marteyn, Yves-Marie Coic, Francoise Baleux, Philippe Sansonetti
  • Patent number: 9907860
    Abstract: This invention relates to a conjugated molecule comprising a peptide derived from the CD4 receptor coupled to an organic molecule by means of a linker as well as a process for its preparation. Said organic molecule comprises a 5 to 21 amino acid anionic polypeptide. Such a conjugated molecule can be used in antiviral treatment, namely in the treatment of AIDS.
    Type: Grant
    Filed: October 23, 2015
    Date of Patent: March 6, 2018
    Assignees: INSTITUT PASTEUR, COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES, UNIVERSITE PARIS-SUD, UNIVERSITE GRENOBLE ALPES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Francoise Baleux, Hugues Lortat-Jacob, David Bonnaffe, Yves-Marie Coic
  • Publication number: 20170326246
    Abstract: This invention relates to a conjugated molecule comprising a peptide derived from the CD4 receptor coupled to an organic molecule by means of a linker as well as a process for its preparation. Said organic molecule comprises a 5 to 21 amino acid anionic polypeptide. Such a conjugated molecule can be used in antiviral treatment, namely in the treatment of AIDS.
    Type: Application
    Filed: October 23, 2015
    Publication date: November 16, 2017
    Inventors: Francoise BALEUX, Hugues LORTAT-JACOB, David BONNAFFE, Yves-Marie COÏC
  • Publication number: 20160318981
    Abstract: The invention relates to polypeptides, defined through a consensus sequence, having a length from 10 to 80 amino-acid residues, and whose polypeptidic sequence comprises or consists of the consensus sequence P1(Xa)P3(Xb)P5(Xc)P6(Xd)P7 (SEQ ID NO: 1), presenting specific patterns. The polypeptides of the invention target glycosylated Muc2 proteins. The invention also relates to methods of synthesis of such polypeptides, to their nucleic acids and uses thereof. The polypeptidic sequence of the polypeptides of the invention can be part of the N-terminal sequence of a mucus-binding (MUB) domain, especially a mucus-binding (MUB) domain of several species. The invention also relates to chimeric molecule(s) comprising such polypeptides, which are labelled, and vectors, especially plasmids and population of cells or composition comprising polypeptides of the invention. Synthesis methods encompass biotechnological or chemical production.
    Type: Application
    Filed: June 9, 2016
    Publication date: November 3, 2016
    Applicant: INSTITUT PASTEUR
    Inventors: Benoit Marteyn, Yves-Marie Coic, Francoise Baleux, Philippe Sansonetti
  • Patent number: 9446109
    Abstract: A conjugate molecule comprising an oligo- or polysaccharide covalently bound to a carrier and its use as potential vaccine against infection by S. Flexneri.
    Type: Grant
    Filed: December 14, 2011
    Date of Patent: September 20, 2016
    Assignee: INSERM (Institut National De La Sante Et De La Recherche Medicale)
    Inventors: Armelle Phalipon, Farida Nato, Laurence Mulard, Philippe Sansonetti, Françoise Baleux, Frédéric Belot, Cyrille Grandjean
  • Patent number: 9382299
    Abstract: The invention relates to polypeptides, defined through a consensus sequence, having a length from 10 to 80 amino-acid residues, and whose polypeptidic sequence comprises or consists of the consensus sequence P1(Xa)P3(Xb)P5(Xc)P6(Xd)P7 (SEQ ID NO: 1), presenting specific patterns. The polypeptides of the invention target glycosylated Muc2 proteins. The invention also relates to methods of synthesis of such polypeptides, to their nucleic acids and uses thereof. The polypeptidic sequence of the polypeptides of the invention can be part of the N-terminal sequence of a mucus-binding (MUB) domain, especially a mucus-binding (MUB) domain of several species. The invention also relates to chimeric molecule(s) comprising such polypeptides, which are labelled, and vectors, especially plasmids and population of cells or composition comprising polypeptides of the invention. Synthesis methods encompass biotechnological or chemical production.
    Type: Grant
    Filed: September 7, 2012
    Date of Patent: July 5, 2016
    Assignee: Institut Pasteur
    Inventors: Benoit Marteyn, Yves-Marie Coic, Francoise Baleux, Philippe Sansonetti
  • Patent number: 9295730
    Abstract: This invention relates to a conjugated molecule comprising a peptide derived from the CD4 receptor coupled to an organic molecule by means of a linker as well as a process for its preparation. Such a conjugated molecule can be used in antiviral treatment, namely in the treatment of AIDS.
    Type: Grant
    Filed: January 27, 2009
    Date of Patent: March 29, 2016
    Assignees: Institut Pasteur, Commissariat A L'Energie Atomique Et Aux Eneergies Alternatives, Centre National De La Recherche Scientifique (CNRS)
    Inventors: Françoise Baleux, David Bonnaffe, Hugues Lortat-Jacob, Latino Loureiro-Morais
  • Patent number: 9078928
    Abstract: This invention relates to a conjugated molecule comprising a peptide derived from the CD4 receptor coupled to an organic molecule by means of a linker as well as a process for its preparation. Said organic molecule comprises a 5 to 21 amino acid anionic polypeptide. Such a conjugated molecule can be used in antiviral treatment, namely in the treatment of AIDS.
    Type: Grant
    Filed: March 16, 2012
    Date of Patent: July 14, 2015
    Assignee: Institut Pasteur
    Inventors: Françoise Baleux, Hugues Lortat-Jacob, David Bonnaffe
  • Publication number: 20140336119
    Abstract: The invention relates to polypeptides, defined through a consensus sequence, having a length from 10 to 80 amino-acid residues, and whose polypeptidic sequence comprises or consists of the consensus sequence P1(Xa)P3(Xb)P5(Xc)P6(Xd)P7 (SEQ ID NO: 1), presenting specific patterns. The polypeptides of the invention target glycosylated Muc2 proteins. The invention also relates to methods of synthesis of such polypeptides, to their nucleic acids and uses thereof. The polypeptidic sequence of the polypeptides of the invention can be part of the N-terminal sequence of a mucus-binding (MUB) domain, especially a mucus-binding (MUB) domain of several species. The invention also relates to chimeric molecule(s) comprising such polypeptides, which are labelled, and vectors, especially plasmids and population of cells or composition comprising polypeptides of the invention. Synthesis methods encompass biotechnological or chemical production.
    Type: Application
    Filed: September 7, 2012
    Publication date: November 13, 2014
    Applicant: INSTITUT PASTEUR
    Inventors: Benoit Marteyn, Yves-Marie Coic, Francoise Baleux, Philippe Sansonetti
  • Publication number: 20140161793
    Abstract: A conjugate molecule comprising an oligo- or polysaccharide covalently bound to a carrier and its use as potential vaccine against infection by S. Flexneri.
    Type: Application
    Filed: December 14, 2011
    Publication date: June 12, 2014
    Applicants: INSERM, INSTITUT PASTEUR, Centre National De La Recherche Scientifique
    Inventors: Armelle PHALIPON, Farida NATO, Laurence MULARD, Philippe SANSONETTI, Francoise BALEUX, Frederic BELOT, Cyrille GRANDJEAN
  • Publication number: 20140107043
    Abstract: This invention relates to a conjugated molecule comprising a peptide derived from the CD4 receptor coupled to an organic molecule by means of a linker as well as a process for its preparation. Said organic molecule comprises a 5 to 21 amino acid anionic polypeptide. Such a conjugated molecule can be used in antiviral treatment, namely in the treatment of AIDS.
    Type: Application
    Filed: March 16, 2012
    Publication date: April 17, 2014
    Inventors: Françoise Baleux, Hugues Lortat-Jacob, David Bonnaffe
  • Publication number: 20130243751
    Abstract: A conjugate molecule comprising an oligo- or polysaccharide covalently bound to a carrier and its use as potential vaccine against infection by S. Flexneri.
    Type: Application
    Filed: December 14, 2011
    Publication date: September 19, 2013
    Inventors: Armelle PHALIPON, Farida Nato, Laurence Mulard, Philippe Sansonetti, Françoise Baleux, Frédéric Belot, Cyrille Grandjean
  • Patent number: 8124380
    Abstract: A conjugate molecule comprising an oligo- or polysaccharide covalently bound to a carrier and its use as potential vaccine against infection by S. Flexneri.
    Type: Grant
    Filed: July 2, 2004
    Date of Patent: February 28, 2012
    Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), Institut Pasteur, Centre National de la Recherche Scientifique
    Inventors: Armelle Phalipon, Farida Nato, Laurence Mulard, Philippe Sansonetti, Françoise Baleux, Frédéric Belot, Cyrille Grandjean